Approval Status Updates and New Study Data Emphasized in Q3 2025 Multiple Myeloma Market

During Q3 2025, companies within the multiple myeloma market presented press releases discussing FDA approval updates and new clinical trial results. Materials also focused on efficacy and safety data, dosing, and support programs, while one corporation discussed its financial results.

GlaxoSmithKline announced a negative Oncologic Drugs Advisory Committee vote for Blenrep combinations, a Biologics License Application review period extension, and the presentation of data at two conferences.

Johnson & Johnson discussed new study results supporting a “100 percent overall response rate in transplant-eligible patients” with Tecvayli plus Darzalex Faspro.

Press releases from Bristol Myers Squibb touted iberdomide’s new data from the EXCALIBER-RRMM study.

Regeneron informed readers that Lynozyfic was granted an accelerated approval and discussed its Q2 2025 financial results.